339
A
Affinity �� 188, 190, 191, 194, 202, 206, 329
Agglomeration ��231
Aggregations ��22, 37, 40, 41, 102, 203, 229, 231, 264, 274
Amorphous state �� 170, 273
Amphiphilic block copolymers �� 71–81, 222, 225, 228, 303
Amphiphilic diblock copolymer ��222
Amphiphilic triblock hybrid terpolymer ��144
Angiotensin converting enzyme (ACE) ��100
Angiotensin II type 1 receptor blockers��110
Aniline derivatives �� 18, 20, 21
Antibacterial �� 205, 266–267
Anticancer ��72, 214, 248, 249, 252, 255
Anticancer agents ��199, 328, 330, 336
Anticancer drugs ��86–88, 149, 176, 199, 200,
202–204, 206, 248, 250, 253, 254
Antifungal ��262–264
Anti-hypertensive drugs �� 45, 190
Anti-inflammatory �� 4, 5, 72, 204, 256, 258, 259, 275
Antioxidants ��4, 5, 42, 72, 252, 264–266,
270, 285, 286
Anti-seizure ��269
Antiviral ��259–262
Anti-zika ��267
Aqueous solutions�� 2, 6, 8, 9, 35, 37, 80, 90,
127, 129, 146, 153, 154, 159, 179, 191, 258
Association constant (K α ) ��189
Asymmetry �� 139, 145
AT1 receptor ��110
Attenuated total reflection-Fourier transform infrared
(ATR-FTIR) �� 76–78, 81
B
γ-benzyl-l-glutamate �� 128, 131, 140, 142, 144
Bilayers �� 100, 222–224, 230, 299–301,
303–306, 308, 309, 318
Bioactive molecules ��1–9, 14, 164, 278
Bioavailability �� 4, 5, 9, 45, 72, 101, 110,
188, 190, 200, 202, 204, 207, 208, 222, 236, 238,
248, 249, 251, 252, 256, 260–266, 268–270, 272,
273, 275, 287, 300, 316, 328, 329
Biocompatibility ��152, 203–205, 260
Biodegradable ��71, 100, 136, 152
Biomaterials ��13, 164, 221, 227, 231, 300
Biomolecules �� 4, 14–15, 17, 19–22, 112
Biopharmaceutical classification system (BCS) �� 4, 100,
255, 261, 263, 264, 266, 268, 269
Block copolymers �� 71, 72, 76, 77, 300, 303
Blood-brain barrier (BBB) �� 236, 237
Blood pressure regulators ��110
Bovine serum albumin (BSA)��14, 30, 273, 274
Brain exosomes ��27
C
Caffeic acid (CA) ��4
Calixarenes ��238
Cancer ��5, 25, 72, 86–89, 100, 110,
127, 128, 136, 137, 140, 151, 175, 199–203, 214,
216, 248–250, 252–256, 271, 327–330
Cancer cells ��72, 86, 88, 89, 137, 201–203,
214, 216, 249, 250, 253–255, 327, 328
Candesartan (CAN) ��4, 6, 9, 45–69
Candesartan cilexetil �� 4, 45–69
Captopril ��100–106
Carbon nanohorns ��13–22
13
C cross polarization/magic-angle spinning
(
13
C CP/MAS) �� 318, 319, 323
Cell cultures �� 25, 26, 90–93, 142, 178
Cell growth �� 200, 201, 254
Ceramidase inhibitors��202
Ceranib-2 (C-2) ��199–217
Characteristic transition temperatures ��167, 168, 225, 302
Characterizations �� 22, 25–33, 143, 148,
151–160, 163, 180, 210, 266, 271, 332–333
Chemical shift changes ��319
Chemical stability �� 2, 71, 316
Chimeric nanosystems ��221–232
Circular dichroism ��129
CO 2 laser �� 14, 17
Complexation �� 2, 3, 5, 46, 164, 165, 167,
169, 170, 177, 189–191, 235–245, 250, 251, 258,
262, 264, 270, 271, 273, 314, 319
Complexation energy��46
Complexes �� 1–9, 35, 46, 49–52, 59, 66–68, 92,
100, 102, 110, 111, 113, 115–119, 136, 149,
164–172, 176, 179, 182, 184, 185, 188, 189, 194,
201, 238, 239, 241, 242, 244, 248, 249, 251, 252,
255, 256, 259–262, 264–266, 268, 272, 273, 278,
287–289, 292–296, 304–306, 313–322
Index
Thomas Mavromoustakos et al. (eds.), Supramolecules in Drug Discovery and Drug Delivery: Methods and Protocols,
Methods in Molecular Biology, vol. 2207, https://doi.org/10.1007/978-1-0716-0920-0
© Springer Science+Business Media, LLC, part of Springer Nature 2021

- 339/344